Table 4. Molecular analyses of the 40 treated patients treated on Phase I trials.
| Molecular mutation or aberration | Number of patients tested | Number of patients with a mutation or aberration |
|---|---|---|
| KRAS | 11 | 2 |
| NRAS | 7 | 0 |
| BRAF | 10 | 0 |
| CKIT | 3 | 0 |
| EGFR | 10 | 0 |
| PI3K | 9 | 0 |
| GNAQ | 1 | 0 |
| PTEN Loss | 3 | 0 |
| ER IHC | 6 | 0 |
| PR IHC | 6 | 0 |
| HER-2/neu FISH | 8 | 1 |
Abbreviations: IHC immunohistochemistry; FISH fluorescence in situ hybridization